Skip to main content
Premium Trial:

Request an Annual Quote

Gyros Partners with EMD Millipore to Develop and Commercialize Immunoassays on Gyrolab Platform

Premium

Gyros this week announced a partnership with EMD Millipore to develop, manufacture, and commercialize immunoassay kits for the Gyrolab platform.

The new kits will take advantage of the capabilities of Gyros' microfluidic technology, which, according to the company, requires smaller sample and reagent volumes and offers increased dynamic range and reduced cross-talk and matrix interference compared to traditional ELISAs.

“We are very pleased to be able to partner with Gyros to fill a commercial need to provide immunoassay kits requiring only nanoliter sample volume on a truly high-throughput platform,” Jehangir Mistry, general manager, Multiplex & Immunoassays at EMD Millipore, said in a statement.

Financial and other terms of the agreement were not disclosed.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.